(:AXLA)

Sep 14, 2023 04:30 pm ET
Axcella Announces Reverse Stock Split Effective September 19, 2023
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company’s common stock is expected to commence trading on a split-adjusted basis when the markets open on Septem
Sep 11, 2023 09:31 am ET
Thinking about buying stock in Tivic Health Systems, Axcella Health, Biocept, Aravive, or Uranium Royalty Corp?
NEW YORK, Sept. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TIVC, AXLA, BIOC, ARAV, and UROY.
Aug 29, 2023 08:00 am ET
Axcella Granted Patent for Long COVID Fatigue Treatment
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue. The patent was issued on August 29, 2023, with anticipated expiration in 2042.
Aug 03, 2023 07:30 am ET
Axcella Reports Second Quarter Financial Results and Provides Business Update
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update.
May 04, 2023 04:30 pm ET
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
Apr 17, 2023 08:00 am ET
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two oral presentations of results from the Phase 2a clinical trial of AXA1125 in the treatment of Long COVID Fatigue at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), as a hybrid event both online and in Copenhagen, Denmark on April 15-18, 2023.
Mar 30, 2023 08:00 am ET
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
Feb 15, 2023 04:10 pm ET
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. Food and Drug Administration (FDA). The company reported that it had received regulatory guidance from the FDA, supporting a trial that is designed to serve as the registration trial for patients with Long COV
Feb 09, 2023 04:45 pm ET
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities’ 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023.
Jan 23, 2023 04:15 pm ET
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue. The company reported that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U.K.’s regulatory agency, supporting a single trial that could serve as the registration trial for patients with Long COVID fatigue, and aligning on key measurements
Dec 19, 2022 10:02 am ET
Thinking about buying stock in SINTX Technologies, Cosmos, Core Scientific, TAL Education, or Axcella Health?
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, COSM, CORZ, TAL, and AXLA.
Dec 14, 2022 08:01 pm ET
Axcella Announces Program Reprioritization and Corporate Restructuring
Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. The company has initiated a process to explore a range of strategic alternatives to maximize shareholder value and is working with an investment bank to act as a strategic advisor for this process. As part of this repositioning, and to align with its current capital constraints, the co
Nov 03, 2022 09:59 am ET
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022.
Nov 01, 2022 07:00 am ET
Axcella Reports Third Quarter Financial Results and Provides Business Update
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
Oct 27, 2022 08:30 am ET
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its third quarter 2022 financial results and other business updates on November 1, 2022. The company will host a conference call at 8:30am ET that morning.
Oct 14, 2022 01:24 pm ET
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6th Annual NASH Investor Conference taking place virtually on October 17th, 2022.
Oct 13, 2022 08:00 am ET
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 20,847,888 shares of common stock (the “Shares”) at a purchase price of $1.64 per share, resulting in gross proceeds of $34.2 million, including $6.0 million received as the cancellation of indebtedness upon the conversion of unsecured subordinated convertible promissory notes
Sep 29, 2022 08:32 am ET
Thinking about buying stock in Axcella Health, Century Aluminum, Senti Biosciences, Camber Energy, or Aditxt?
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXLA, CENX, SNTI, CEI, and ADTX.
Sep 29, 2022 06:00 am ET
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported interim results from their ongoing global Phase 2b randomized, double-blind, placebo-controlled, dose ranging EMMPACT study to evaluate the safety, tolerability, and efficacy of AXA1125 for the treatment of NASH. These interim results report findings regarding the effects of AXA1125 administration on selected outcome measures after 12- and 24-weeks of treatment.
Sep 12, 2022 08:00 am ET
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place September 12 – 14, 2022 both virtually and in-person in New York City.
Aug 12, 2022 07:30 am ET
Axcella Reports Second Quarter Financial Results and Provides Business Update
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
Aug 02, 2022 06:00 am ET
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.
May 26, 2022 07:00 am ET
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical trial in Long COVID. The company affirmed topline data readout for its Phase 2a Long COVID trial in early Q3 2022 and interim data readout for NASH in late Q3 2022. The company is suspending its Phase 2 clinical trial in OHE (Overt Hepatic Encephalopathy) while exploring pote
May 19, 2022 08:00 am ET
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23 – 26, 2022 both virtually and in-person in Miami, Florida.
May 05, 2022 07:00 am ET
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
Mar 30, 2022 07:32 am ET
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
Mar 23, 2022 07:02 am ET
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022. The company will host a conference call at 8:30 a.m. ET that morning.
Mar 16, 2022 08:15 am ET
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock (the “Shares”) at a purchase price of $1.91 per share, resulting in gross proceeds of $25.0 million.
Feb 28, 2022 08:00 am ET
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of
Feb 15, 2022 09:05 am ET
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.
Feb 14, 2022 08:31 am ET
Thinking about buying stock in Cornerstone Building Brands, Sundial Growers, Axcella Health, Oscar Health, or AngloGold Ashanti?
NEW YORK, Feb. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNR, SNDL, AXLA, OSCR, and AU.
Feb 14, 2022 07:58 am ET
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. AXA1125 is a multi-targeted oral drug candidate that is currently being investigated in the
Feb 10, 2022 07:30 am ET
Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that company management will be participating in the SVB Leerink Global Healthcare Conference.
Feb 07, 2022 07:55 am ET
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced the appointment of Robert Crane as the company’s new Chief Financial Officer.
Jan 06, 2022 07:58 am ET
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today outlined key clinical and operational milestones that are expected for the company in 2022.
Jan 04, 2022 07:58 am ET
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that President and Chief Executive Officer Bill Hinshaw will be presenting at the H.C. Wainwright BioConnect Conference.
Dec 16, 2021 07:28 am ET
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, and researchers at the Oxford University Radcliffe Department of Medicine today announced that patient screening is now underway in a Phase 2a trial that is investigating AXA1125, an oral product candidate, as a potential treatment for Long COVID, also known as Post COVID-19 Condition and post-acute sequelae of SARS-COV-2 infection (PASC).
Dec 06, 2021 07:50 am ET
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical Officer and added as a member of the company’s executive team. Dr. Koziel, who previously served as Vice President, Clinical Development, joined Axcella in 2019, bringing a wealth of leadership experience within both biopharma and academia.
Nov 18, 2021 07:58 am ET
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in the Piper Sandler 33rd Annual Healthcare Conference.
Nov 10, 2021 07:58 am ET
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
Nov 02, 2021 07:58 am ET
Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually November 12-15, 2021. These presentations will include further data regarding AXA1125 for nonalcoholic steatohepatitis (NASH) and AXA1665 for overt hepatic encephalopathy (OHE). Further information is a
Oct 26, 2021 06:58 am ET
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced a new clinical program to investigate AXA1125 as a potential treatment for patients with Long COVID, a complex condition also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC). The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) accepted a Phase 2a clinical trial authorization (CTA) submission from Axcella on October 22, 2021.
Oct 19, 2021 07:58 am ET
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions, today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET. The event will feature presentations from multiple key opinion leaders (KOLs) as well as Axcella’s management team. Topics will include the company’s next clinical program (to be announced the day of the event), its ongoing programs in overt hepatic encephalopathy (OHE) and non-alcoholic steatohepatitis (NASH), an
Oct 13, 2021 10:00 am ET
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
CAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
Oct 05, 2021 07:58 am ET
Axcella Announces Upcoming Investor Conference Presentation
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.
Sep 07, 2021 07:58 am ET
Axcella Announces Upcoming Investor Conference Presentation
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.
Aug 16, 2021 07:58 am ET
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the publication of results from the company’s AXA1125-003 clinical study in The American Journal of Gastroenterology entitled
Jul 29, 2021 07:28 am ET
Axcella Reports Second Quarter Financial Results and Provides Business Update
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
Jul 22, 2021 07:28 am ET
Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference ca
Jun 30, 2021 07:28 am ET
Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and patient screening for its global Phase 2 clinical trial of AXA1665, the company’s multi-targeted oral p
Jun 14, 2021 09:31 am ET
Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?
NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA.
May 24, 2021 07:28 am ET
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that positive data from the company’s AXA1665-002 clinical study were presented last night at the Digestive Disease Week (DDW) 2021 Annual Meeting by Dr
May 11, 2021 07:55 am ET
Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targete
May 11, 2021 07:28 am ET
Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targete
May 06, 2021 07:28 am ET
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.
Apr 27, 2021 07:28 am ET
Axcella to Report First Quarter 2021 Financial Results on May 6, 2021
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021. The company will host a conference call
Apr 22, 2021 07:28 am ET
Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company’s product candidate for the reduction in risk of recurrent overt
Apr 13, 2021 07:28 am ET
Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has achieved a key milestone with U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for AXA1125
Mar 17, 2021 07:28 am ET
Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.
Mar 10, 2021 08:00 am ET
Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and full year 2020 financial results and other business updates on March 17, 2021. The company will host
Mar 03, 2021 04:20 pm ET
Axcella Announces Alison D. Schecter, M.D., as President of R&D
Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakravarthy, M.D., Ph.D., has decided to step down as the company’s Chief Medical Officer to pursue another opportunity.
Feb 25, 2021 07:55 am ET
Axcella Announces Upcoming Presentations at NASH-TAG 2021
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced three upcoming presentations at the NASH-TAG 2021 Conference, which is taking place March 11-13. Among the information to be shared by Axcella at this e
Feb 25, 2021 06:00 am ET
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds and accounts managed by BlackRock, The Baupost Group, Banque Pictet on behalf of their clients and eight other investors alongside Flagship Pioneering.
Feb 18, 2021 07:55 am ET
Axcella to Present at Upcoming Investor Conferences
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will participate in the following upcoming investor conferences:
Jan 11, 2021 07:58 am ET
Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced clearance of the company’s first investigational new drug (IND) filing and provided an update on its product candidates, research and development activities and expected milestones for 2021.
Jan 05, 2021 07:58 am ET
Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the J.P. Morgan 2021 Healthcare Conference on January 14, 2021 at 10:00 a.m. ET.
Nov 20, 2020 07:30 am ET
Axcella Announces Upcoming Investor Conference Presentation
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference. The company will be webcasting its fireside ch
Nov 13, 2020 07:30 am ET
Axcella Presents Data for AXA1125 at The Liver Meeting® 2020
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today shared details about the company’s poster presentations at The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases
Nov 12, 2020 07:30 am ET
Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2020 and provided a business update.
Oct 29, 2020 08:00 am ET
Axcella to Report Third Quarter 2020 Financial Results and Hold Conference Call on November 12, 2020
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its third quarter financial results and other business updates on November 12, 2020. The company will host a conference call
Oct 02, 2020 07:58 am ET
Axcella Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases
Sep 30, 2020 07:28 am ET
New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced a new publication detailing the potential for the development of EMM compositions that simultaneously target multiple biological pathways and address un
Sep 29, 2020 07:58 am ET
Axcella Announces Upcoming Investor Conference Presentation
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in a fireside chat at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020 at 1:30 p.m.
Sep 24, 2020 03:35 pm ET
Company Profile for Axcella Health Inc.
Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-relate
Sep 08, 2020 08:00 am ET
Axcella to Present at Upcoming Investor Conferences
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the following upcoming conferences:
Aug 27, 2020 08:00 am ET
Axcella’s Late-Breaker Data from AXA1125-003 Clinical Study Presented at the EASL Digital International Liver Congress
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, announced that data are being presented today in a late-breaker poster regarding key findings from its AXA1125-003 clinical study by Stephen A. Harrison, M.D
Aug 20, 2020 07:30 am ET
Axcella Announces Upcoming Later-Breaker Presentation at The Digital International Liver Congress 2020
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced an upcoming late-breaker poster presentation at The Digital International Liver Congress™ 2020 (EASL), which is
Aug 17, 2020 07:30 am ET
Results of Axcella’s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the publication of results from the company’s AXA1665-001 clinical study in Clinical and Translational Gastroenterology entitled
Aug 05, 2020 10:41 am ET
CORRECTING and REPLACING Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results
Table titled "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss," columns "Six Months Ended June 30, 2020 and 2019," have been replaced.
Aug 05, 2020 07:30 am ET
Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today reported positive top-line 12-week data from AXA1665-002, a placebo-controlled clinical study of AXA1665, and financial results for the second quarter ended June 30, 2020.
Aug 03, 2020 08:00 am ET
Axcella to Report Second Quarter 2020 Financial Results and Hold Conference Call on August 5, 2020
The conference call webcast and accompanying slides will be made available shortly before the start of the call on the company’s website at www.axcellahealth.com in the Investors & News section. To access the call via telephone, please dial (866) 652-5200 (U.S. toll free) or (412) 317-6060 (international) five minutes prior to the start time.
Jul 07, 2020 08:00 am ET
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.
Jun 17, 2020 08:00 am ET
Axcella Announces Patent Issuances Covering AXA1665
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the issuance of two new patents: U.S. Patent 10,682,325 and U.S. Patent 10,660,870. These are the first patents related to Axcella’s family o
Jun 03, 2020 08:00 am ET
Axcella to Present at Goldman Sachs 41st Annual Global Healthcare Conference
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the Goldman Sachs 41st Annual Global Healthcare Conference, which is being held virtually, on June
May 28, 2020 09:31 am ET
Thinking about buying stock in Aerpio Pharmaceuticals, Axcella Health, General Electric, Zomedica Pharmaceuticals, or Avis Budget Group?
NEW YORK, May 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARPO, AXLA, GE, ZOM, and CAR.
May 28, 2020 08:00 am ET
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
CAMBRIDGE, Mass., May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.
May 18, 2020 04:05 pm ET
Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the closing of its underwritten public offering of an aggregate of 12,650,000 shares of its common stock, including the full exercise of the
May 13, 2020 10:31 pm ET
Axcella Announces Pricing of Public Offering of Common Stock
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the pricing of its underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $4.75 per share, befor
May 11, 2020 08:00 am ET
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced financial results for the first quarter ended March 31, 2020 and provided a business update.
May 06, 2020 08:00 am ET
Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced positive top-line data from AXA1125-003.
May 05, 2020 04:05 pm ET
Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD on May 6, 2020
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it plans to report top-line data from AXA1125-003 on May 6, 2020 and will host a conference call at 8:30 a.m. ET that morning. AXA11
May 04, 2020 04:05 pm ET
Axcella to Hold Virtual-Only 2020 Annual Meeting of Stockholders
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format due to the continued public health impact of the coronavir
Apr 07, 2020 08:00 am ET
Axcella Receives Fourth Patent Covering EMM Compositions
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the issuance of U.S. Patent 10,596,136. This patent broadly covers the use of the company’s initial muscle product candidate, AXA2678, and related EMM compositions for the reduction of fat infiltration in muscle.
Mar 23, 2020 04:01 pm ET
Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Axcella Health Inc. (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.
Mar 05, 2020 08:00 am ET
Axcella Announces Oral Presentation at 2020 International Conference on Frailty and Sarcopenia Research
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it will give an oral presentation at the 2020 International Conference on Frailty and Sarcopenia (ICFSR) in Toulouse, France on March 12, 2020.
Feb 26, 2020 07:30 am ET
Axcella Completes Enrollment of Subjects in AXA1665-002 Study
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it has completed subject enrollment in its ongoing AXA1665-002 clinical study. This 12-week, placebo-controlled, randomized study is investigating the safety, tolerability and physiological impact of two doses of AXA1665 in 60 subjects with mild and moderate hepatic insufficiency. Ongoing safety monitoring in this study supports that both doses of AXA1665 have been well tole
Feb 19, 2020 08:00 am ET
Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the SVB Leerink 9th Annual Global Healthcare Conference in New York City on February 26, 2020 at 9:
Jan 09, 2020 08:00 am ET
Axcella to Present at J.P. Morgan Healthcare Conference
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that President and CEO Bill Hinshaw will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 1
Jan 08, 2020 08:00 am ET
Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today provided an update from its ongoing clinical study in adult subjects with non-alcoholic fatty liver disease (NAFLD) and announced its anticipated m
Dec 07, 2019 08:00 am ET
Axcella Presents Data at ASH Annual Meeting
Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced mechanistic data for AXA4010 that are being presented today at the American Society of Hematology’s (ASH) 2019 Annual Meeting.
Nov 25, 2019 08:00 am ET
Axcella Strengthens Executive Team with Key Addition and Promotion
Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that it has appointed Laurent Chardonnet as the company’s Chief Financial Officer and that it has promoted its Vice President of Legal, Heidy King-Jones, to Ge
Nov 20, 2019 08:00 am ET
Axcella Announces Issuance of Broad Patent Covering EMM Compositions
Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the issuance of U.S. Patent 10,471,034. This is the third EMM-related patent that Axcella has received to date, and it covers an array of EMM compositions, inc
Nov 12, 2019 04:05 pm ET
Axcella Health Reports Third Quarter 2019 Financial Results and Provides Company Update
Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced financial results for the third quarter ended September 30, 2019 and provided a company update.
Nov 08, 2019 08:00 am ET
Axcella Presents Data at The Liver Meeting™ Providing New Mechanistic Insights on Observed Multifactorial Effects of its Liver Product Candidates
Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel interventions to address dysregulated metabolism and support health, today announced that it will present new data on the company’s liver product candidates at The Liver MeetingTM, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held this week in Boston. Two poster presentations highlight mechanistic data from preclinical and non-IND clinical studies of two of its investigational candidates, AXA1665 and AXA1125.
Nov 06, 2019 08:00 am ET
Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010
Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced key milestones in the development of AXA4010, the company’s first investigational hematology product candidate. Mechanistic data on AXA4010 will be p
Oct 23, 2019 07:30 am ET
Axcella Enters into Collaboration with CYTOO to Explore Impact of Dysregulated Metabolism on Muscle Physiology
Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced a collaboration with CYTOO aimed at informing the development of new AXA Candidates by leveraging CYTOO’s MyoScreenTM muscle-on-a-plate platform. Th
Oct 07, 2019 08:30 am ET
Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957
Axcella Health Inc., (Nasdaq: AXLA) (“Axcella or the Company”) a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced liver program progress updates regarding the development of AXA1125 and AXA1957.
Oct 01, 2019 04:11 pm ET
Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting
Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that the company will present two posters for two of its liver health-focused AXA candidates, AXA1665 and AXA1125 at the American Assoc
Aug 23, 2019 04:27 pm ET
Axcella Health Inc. Announces Appointment of Catherine A. Sohn, Pharm. D. to its Board of Directors
Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions using novel compositions of endogenous metabolic modulators to address dysregulated metabolism and support health, today announced that Catherine A. Sohn, Pharm.D. has been appointed to its Board of Directors. In addition, the Company announced that Christopher A. Viehbacher is stepping down after serving as a Board member since 2015.
Aug 12, 2019 05:06 pm ET
Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update
Axcella Health Inc. (Nasdaq: AXLA) (“Axcella” or the “Company”), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced financial results for the second quarter ended June 30, 2019 and provided a company update.
Aug 07, 2019 05:54 pm ET
Axcella to Present at the Wedbush PacGrow Healthcare Conference
Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that Bill Hinshaw, President and CEO, will present a corporate update at the Wedbush PacGrow Healthcare Conference, which is taking place at the
Jul 31, 2019 08:00 am ET
Axcella Announces Publication of Data Describing Attenuation of Muscle Atrophy with AXA2678 in Short-Term Muscle Disuse Study
Axcella Health, (Nasdaq: AXLA) (“Axcella” or the “Company”), a biotechnology company pioneering the research and development of novel multifactorial interventions using novel compositions of endogenous metabolic modulators to address dysregulated metabolism and support health, announced the publication of data describing the safety,
Jun 20, 2019 05:10 pm ET
Axcella Health Reports First Quarter 2019 Financial Results and Provides Company Update
Axcella Health, Axcella Health Inc. (Nasdaq: AXLA) (“Axcella” or the “Company”), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today...
May 13, 2019 05:30 pm ET
Axcella Health Announces Closing of Initial Public Offering
Axcella Health Inc., a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the closing of its initial public offering of...
May 08, 2019 08:40 pm ET
Axcella Health Announces Pricing of Initial Public Offering
Axcella Health Inc., a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the pricing of its initial public offering of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.